Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
147 hedge funds and large institutions have $1.56B invested in Five Prime Therapeutics, Inc. in 2021 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 37 increasing their positions, 33 reducing their positions, and 43 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
134% more capital invested
Capital invested by funds: $664M → $1.56B (+$893M)
51% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 43
18% more funds holding
Funds holding: 125 → 147 (+22)
12% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 33
60% less call options, than puts
Call options by funds: $12.1M | Put options by funds: $30M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$132M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$60M |
| 3 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$50.1M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$48.4M |
| 5 |
Goldman Sachs
New York
|
+$29.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$72.9M |
| 2 |
RI
RTW Investments
New York
|
-$42.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$41.6M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$26.6M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$21.6M |
FPRX Hedge Fund Activity: Q1 2021 in Review
147 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q1 2021, worth a combined $1.56B — up 134% from $664M a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new FPRX positions and 43 closed out — a net gain of 22 holders — while 37 added to existing stakes and 33 trimmed.
The largest buyer was BVF Inc, adding an estimated $132M. The largest seller was RA Capital Management, exiting entirely with an estimated $72.9M sold.
- 147 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q1 2021, up from 125 in Q4 2020.
- Funds reported $1.56B of Five Prime Therapeutics, Inc. stock for Q1 2021, up 134% quarter-over-quarter.
- 65 funds opened new Five Prime Therapeutics, Inc. positions in Q1 2021 and 43 closed out, a net change of +22 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q1 2021 was BVF Inc, an estimated $132M added.
- The largest Five Prime Therapeutics, Inc. seller in Q1 2021 was RA Capital Management, an estimated $72.9M sold.
Based on aggregated 13F filings for Q1 2021.